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.2013.01.0Abstract The clinical manifestations of schistosomiasis pass by acute, sub acute and chronic stages
that mirror the immune response to infection. The later includes in succession innate, TH1 and TH2
adaptive stages, with an ultimate establishment of concomitant immunity. Some patients may also
develop late complications, or suffer the sequelae of co-infection with other parasites, bacteria or
viruses. Acute manifestations are species-independent; occur during the early stages of invasion
and migration, where infection-naivety and the host’s racial and genetic setting play a major role.
Sub acute manifestations occur after maturity of the parasite and settlement in target organs. They
are related to the formation of granulomata around eggs or dead worms, primarily in the lower uri-
nary tract with Schistosoma haematobium, and the colon and rectum with Schistosoma mansoni,
Schistosoma japonicum, Schistosoma intercalatum and Schistosoma mekongi infection. Secondary
manifestations during this stage may occur in the kidneys, liver, lungs or other ectopic sites. Chronic
morbidity is attributed to the healing of granulomata by ﬁbrosis and calciﬁcation at the sites of oval
entrapment, deposition of schistosomal antigen-antibody complexes in the renal glomeruli or the
development of secondary amyloidosis. Malignancy may complicate the chronic lesions in the uri-
nary bladder or colon. Co-infection with salmonella or hepatitis viruses B or C may confound the
clinical picture of schistosomiasis, while the latter may have a negative impact on the course of other
co-infections as malaria, leishmaniasis and HIV. Prevention of schistosomiasis is basically geared
around education and periodic mass treatment, an effective vaccine being still experimental. Prazi-
quantel is the drug of choice in the treatment of active infection by any species, with a cure rate of
80%. Other antischistosomal drugs include metrifonate for S. haematobium, oxamniquine for S.
mansoni and Artemether and, possibly, Mirazid for both. Surgical treatment may be needed for
ﬁbrotic lesions.
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05Introduction
Genus schistosoma (Fig. 1, [1]) is a very well-preserved parasite
across millions of years. DNA sequencing suggests that it had
originated as a hippo parasite during the Cenozoic era [2].
Over so many decades, it must have been responsible for.V. All rights reserved.
Fig. 1 Life cycle of schistosoma [1] (With permission).
434 R.S. Barsoum et al.morbidity and mortality of hundreds of million humans in
underprivileged communities.
A few decades ago, the World Health Organization had
started the implementation of schistosomiasis control pro-
grams in nations where the disease was endemic. The outcomes
were variable, with complete eradication in certain countries
like Japan, and actual increase in disease prevalence in others
as certain areas in China [3]. The overall current global preva-
lence ranges 230–240 millions. (See Barakat’s article on Epide-
miology of Schistosomiasis in Egypt in this issue of the Journal).
Interestingly, despite the ready availability of inexpensive,
effective single dose oral treatment, only 33.5 millions received
treatment in 2010 [4]. This gap is partly attributed to theFig. 2 Broad correlations of schistosomiasis clinical proﬁles with
response, and respective pathological lesions.relatively low infection-related serious morbidity. While about
60% of infected patients are symptomatic, only 10% have seri-
ous disease urging them to seek medical advice. Disease-related
mortality is low, amounting to only 200,000 (0.1% of infected
patients) per annum, across the globe. Ninety percent of these
are inhabitants of sub-Saharan Africa; hence the disease bur-
den is disproportionately high in that part of the world.
Parasitization per se is relatively harmless. Its only clinical
manifestations are terminal dysuria, hematuria and occasion-
ally dysentery. Almost all other clinical features of schistosomi-
asis are caused, directly or indirectly, by the host’s immune
response to different stages of the parasite’s life cycle in the
body. Yet this immune response is a double-faced coin, beingthe progression of the parasite’s life cycle in vivo, host immune
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tion and reducing its pathogenicity. T-cell deﬁcient nude mice
experimentally infected with schistosomes die rapidly with mas-
sive cercarial tissue invasion [5]. But even competent mamma-
lian immunity fails to completely eradicate schistosomal
infection. It can only establish a host-parasite balanced inter-
relationship that keeps both alive, with reduced parasite’s fertil-
ity, limited patient morbidity and resistance to re-infection.
This status is often referred to as ‘‘concomitant immunity’’.
Therefore, it is not unexpected that the clinical proﬁle of
schistosomiasis mirrors the progression of the host’s immune
response to the process of parasite’s maturation (Fig. 2). This
concept is very well displayed in the typical clinical syndromes
in schistosomiasis, which may be classiﬁed under the conve-
nient broad titles acute, sub acute and chronic manifestations,
late complications, and the composite sequelae of co-infection
with other biological agents including parasites, bacteria and
different viri.Acute manifestations
These coincide with the invasion and migration stages of the
parasite’s life cycle, during which the immune response is ini-
tially innate, confounded a few days later by a TH1-dominant
adaptive response. They may occur with any schistosomal spe-
cies, most prominently Schistosoma japonicum. Most reported
cases are infection-naı¨ve expatriates, though super infection in
previously infected subjects may also lead to pulmonary or sys-
temic acute manifestations [6]. Four acute presentations are
recognized:
Swimmer’s itch
This is a local inﬂammatory, hardly visible wheel at the site of
cercarial penetration, composed of edema, dilated capillaries
and a few cells, attributed to the local release of monokines.
The duration and severity of this reaction depend on the length
of schistosomular stay in the dermis. Therefore, the lesion is
most pronounced in infections with non-human-pathogenic
species of the parasite, whose schistosomulae cannot migrate.
An Arthus skin reaction has been occasionally described in
expatriates acquiring infection in endemic areas.
Cercarial dermatitis
A temporary itchy maculopapular skin eruption, comprising
discrete, 1 cm to 3 cm erythematous raised macules, may devel-
op at the site of percutaneous penetration by schistosomal
cercariae. Although pathogenetically similar to the ‘‘swimmers
itch’’, this visible reaction develops in sensitized people when
they are re-infected by schistosomal species that do not colo-
nize in humans [7].
Bronchopneumonia
Bronchial hyper-reactivity with radiologically demonstrable
pulmonary inﬁltrates may occur during the migration of schist-
osomulae through the pulmonary capillaries [8]. It is attributed
to monokines and the TH1 cytokines that start to confound the
immune response. It may also occur with superinfection inpreviously infected people [6]. Rebound epidemics have been
reported in Chinese endemic communities exposed to ﬂoods [9].
Katayama syndrome
This is a delayed hypersensitivity reaction that may occur 4–
8 weeks after infection, coinciding with worm maturity [6].
The supervening immune response proﬁle is TH1 dominated.
The syndrome is characterized by fever, arthralgia and vasculit-
ic skin eruption. Eosinophila and high serum IgM are typical.
Cryoglobulinemia has occasionally been described. Most pa-
tients recover spontaneously after 2–10 weeks, but some devel-
op persistent and more serious disease with weight loss,
dyspnoea, and diarrhoea, diffuse abdominal pain, toxaemia,
hepatosplenomegaly and widespread rash. It can evolve rapidly
to hepatic ﬁbrosis, splenomegaly and portal hypertension [10].
Sub acute manifestations
The early clinical manifestations of established schistosomal
infection are dominated by sub acute inﬂammatory lesions in
certain organs, attributed to a supervening TH1 pro-inﬂamma-
tory immune reaction, in concert with a building up TH2 re-
sponse. The lesions are species- and organ-speciﬁc and
depend on the provocative antigens, whether locally released
from deposited eggs [11] or circulating upon regurgitation of
adult worm gut juices [12]. The former lead to a granuloma-
tous, predominantly cell-mediated inﬂammation in affected or-
gans, while the latter lead to predominantly antibody-mediated
glomerulonephritis.
Granulomatous lesions
Since the main target of the parasite is to expel its ova to the
external environment in order to maintain species survival,
the worms lay their eggs as near as possible to the exterior;
the urinary bladder in Schistosoma haematobium infection
and the distal colon and rectum in Schistosoma mansoni, S.
japonicum, Schistosoma intercalatum and Schistosoma mekongi
infections. These sites, therefore, are those of the earliest and
worst pathology, hence the term ‘‘primary targets’’. These le-
sions spell over into ‘‘secondary targets’’ by different mecha-
nisms. The upper urinary tract may be involved as a result
of obstruction or reﬂux at the uretero-vesical junctions. The li-
ver is usually involved as a result of drifting ova with the portal
blood stream. The lungs may be a secondary target as ova are
driven with the blood circulation, having reached the vena
cava through even the normal porto-systemic anastomoses.
Occasionally, ova may also reach ectopic sites as the brain,
spinal cord, genital organs, skin or eyes, always through
respective venous anastomoses with the inferior vena cava.
Schistosomal granlomata are formed around deposited ova
in all these sites, leading to a succession of sub acute and
chronic lesions and clinical manifestations.
Primary targets
Lower urinary
S. haematobium infection typically involves the bladder, lower
ureters, seminal vesicles, and, less frequently, the vas deferens,
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in the peri-vesical venous plexus, to which they had migrated
earlier on via the porto-systemic anastomosis at the level of
the third lumbar vertebra. The females travel to the bladder
wall driven by the oxygen gradient generated by its urinary
content. There they lay their eggs with the terminal spikes di-
rected towards the bladder lumen, to facilitate extrusion dur-
ing detrusor contraction. Eggs that fail in getting their
freedom remain trapped in the bladder wall; it is these, which
cause the pathological lesions by releasing their antigens and
provoking granuloma formation (Fig. 3, [13]).
Granulomata coalesce to form tubercles, nodules or masses
that often ulcerate. The surrounding mucosa is hyperemic. The
sub mucosa and muscle layers are also involved in the inﬂam-
matory process.
The characteristic clinical presentation is terminal hematu-
ria, usually associated with increased frequency of micturition
and dysuria. In endemic areas, hematuria is the red ﬂag of
schistosomiasis in children aged 5–10 years, sometimes con-
fused with menstruation in girls and even a coming of age in
boys. Typically, blood is ﬁrst seen in the terminal urine, but
in severe cases the whole urine sample can be dark colored.
In a large cross sectional study on an un-treated African pop-
ulation infected with S. haematobium, microhematuria was re-
ported in 41–100%, gross hematuria in 0–97% [14].Fig. 3 Basic histopathological lesion in schistosomiasis. (A)
Active S. mansoni granuloma. Note the central deformed ovum
with a lateral spike and the surrounding mononuclear and few
polymorphonuclear cells. (B) Sheet of live S. haematobium cells.
(C) Multiple granulomata around S. haematobium worms and egg
debris. Note the intact female worm and a coronal section in a
male worm in a bladder venule, and the surrounding mononuclear
cellular reaction and ﬁbrotic granulomata [13] (With permission).Colorectal
This region is targeted in S. mansoni, S. japonicum, S. mekongi
and S. intercalatum infections. Adult worms live in the portal
vein and its tributaries, notably the inferior mesenteric vein, to
which they migrate against the blood stream after prior matu-
ration in the hepatic sinusoids. The worms choose the portal
rather than the systemic veins owing to the former’s higher
content of oxygen and nutrients. Like with S. haematobium,
the females travel further against the blood stream towards
the distal colon and rectum, driven by an oxygen gradient,
to lay their eggs seeking freedom.
All segments of the colon may be affected, yet the rectum,
sigmoid and descending colon, the domain of the inferior mes-
enteric vein, are the main site of pathology in over 90% of
cases [15].
Egg deposition in the sub mucosa leads to granuloma for-
mation, congestion, edema and polyp formation (Fig. 4, [16])
and ulceration. These may lead to abdominal cramping, diar-
rhea which may be bloody, and dysentery. The diagnosis is
made by ﬁnding schistosoma ova in stools, rectal scrapings,
or rectal snips (Fig. 5, [17]). Proctocolonoscopic examination
helps to establish the diagnosis, exclude similar lesions includ-
ing ulcerative and amebic colitis, and to categorize the histopa-
thological patterns.Fig. 4 Schistosomal intestinal polyposis. Extensive granulomas
and polyposis of the sigmoid colon and rectum in a Brazilian
patient with Schistosomiasis mansoni [16].
Fig. 5 Calciﬁed schistosomal ova in a rectai biopsy. Normal
mucosa overlying sub mucosal layer containing numerous calciﬁed
Schistosoma japonicum eggs [17].
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Kidneys
The kidneys are rare sites of asymptomatic ectopic granuloma
formation. On the other hand, early back pressure due to lower
urinary pathology may occur. Radiologically visible lesions in
the upper urinary tract were observed in up to 62% of cases in
a large series from sub-Saharan Africa. Kidneys function was
preserved in most cases [14]. These changes are attributed to oe-
dema of the uretero-vesical junctions, which are close to the area
of heaviest oviposition, the trigone. They are spontaneously
reversible upon resolution of the inﬂammatory oedema.
Back pressure changes may persist if the lower ureters are
involved in the pathological process, with the formation of
granulomata. These are often located in the lower third, and
rarely cross beyond the middle. (See Barsoum’s article on Uri-
nary schistosomiasis in this issue of the Journal).
Liver
Although schistosomulae of all species grow and mature in the
hepatic sinusoids, mature worms soon leave the liver as they
prefer living and copulating in the more spacious, better oxy-
genated portal vein. Yet, the organ is notoriously involved la-
ter on, as ova are driven by the blood stream to settle in the
portal tracts. This is inevitable in the majority of patients with
S. mansoni, S. japonicum, S. intercalatum and S. mekongi infec-
tion. It may also be involved with S. haematobium infection as
a consequence of the escape of ectopic ova into the portal ve-
nous system. Initially, the liver is mildly to moderately en-
larged and tender. Unless the disease is complicated by
concomitant viral infection (usually HCV or HBV), or associ-
ated non-alcoholic steatohepatitis (NASH), tests of hepatocel-
lular function are not signiﬁcantly affected at this stage. A few
weeks to months later, the spleen is also enlarged due to the
lymphoid hyperplasia featuring the host’s immune response.
(See Elbaz and Esmat’s article on Hepatic and Intestinal Schis-
tosomiasis, in this issue of the Journal).
Ectopic lesions
Organs affected by ectopic granulomata include the central
nervous system, genital organs, skin and eyes.Central nervous system
Ectopic ova gain access to the central nervous system through
the anastomosis in between the lumbar veins, which are tribu-
taries of the inferior vena cava, and the internal vertebral ve-
nous plexus. They may deposit and provoke granuloma
formation in the adjacent spinal cord [18], or travel cephalad
during coughing or straining, and impinge into the brain tis-
sue. The small size of S. japonicum eggs facilitates their journey
towards the brain, hence the preference of this species in cere-
bral schistosomiasis, including the cortex, subcortical white
matter, basal ganglia, and internal capsule. On the other hand,
myelopathy of the lumbosacral region is more commonly re-
ported with S. mansoni and S. haematobium infection [19].
Neuroschistosomiasis is the most severe clinical syndrome
associated with schistosomal infection. It includes signs and
symptoms of increased intracranial pressure, myelopathy,
and radiculopathy. The lesions can evolve to irreversible glial
scars if left untreated. Complications of cerebral disease in-
clude encephalopathy with headache, visual impairment, delir-
ium, seizures, motor deﬁcit, and ataxia. Spinal symptoms
comprise lumbar pain, lower limb radicular pain, muscle weak-
ness, sensory loss, and bladder dysfunction.
Genital
Genital schistosomiasis, due to eggs of S. haematobium in the
reproductive organs, is quite common but mostly occult in
some endemic areas and a regular ﬁnding in travellers. Lesions
of the ovaries and the fallopian tubes can lead to infertility. In
men, hemospermia is a common symptom. The epididymis,
testicles, spermatic cord, and prostate can be affected.
[20,21]. Symptoms in female patients include hypertrophic
and ulcerative lesions of the vulva, vagina, and cervix, which
might facilitate sexual transmission of infections. Therefore,
women with urinary/genital schistosomiasis are at an increased
risk of acquiring HIV infection [22] (see later).
Skin
Skin involvement is rare. The most common sites are genital,
where nodular lesions develop in the skin of the scrotum, pe-
nis, and vulva. They are usually asymptomatic, being non-ten-
der, non-itchy, and non-ulcerative. Very rarely, similar lesions
have been reported to occur around the umbilicus and overly-
ing the scapulae and shoulders.
Eyes
Nodular lesions have also been described in the palpebral con-
junctiva in patients with extensive S. haematobium disease.
However, no effects on the eyeball have been reported.
Sub acute immune-complex mediated disease
Proliferative glomerulonephritis, with schistosomal antigen
deposits, has been identiﬁed as a manifestation of early
S. haematobium infection. A unique study was conducted on
the inhabitants of an Egyptian village before and after
S. haematobium was introduced as a consequence of changing
the method of agricultural irrigation from seasonal to perennial.
Transient proteinuria, hematuria and hypertension were noticed
in infected subjects, and renal biopsy showed mesangial prolifer-
ation and inﬁltration with transit pro-inﬂammatory blood cells.
Spontaneous recovery occurred in all patients, but follow
Fig. 6 Advanced urinary schistosomiasis. Post-mortem speci-
men showing dirty thickening of the bladder wall with a neoplastic
growth; dilated right ureter and ureterovesical junction with
multiple nodular lesions (ureteritis cystica), bilateral renal scarring
with dilated right pelvicalyceal system [27] (With permission).
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um-associated glomerulonephritis have been described later [24].
Similar glomerular lesions were also described with S. man-
soni infections, though in less dramatic scenarios. In contrast
to the haematobium-associated lesions they seem to persist
and progress to other forms of glomerulonephritis as described
later.
Schistosoma-associated glomerular lesions are signiﬁcantly
modiﬁed by concomitant infections. Best known is co-infection
with salmonella species, which lead to an exudative glomerulo-
nephritis with sub acute onset of the nephrotic syndrome [25].
More recently, the impact of viral infections, particularly
HCV, was recognized as a cause of accelerated glomerular
pathology, ﬁbrinoid necrosis and crescent formation [26].
(See Barsoum’s article on Urinary Schistosomiasis, in this issue
of the Journal).
Chronic manifestations
Chronicity in schistosomiasis requires switching of the immune
response from a predominantly TH1 pro-inﬂammatory into a
TH2 modulatory proﬁle (Fig. 2). This takes place gradually
over several weeks; coinciding with egg deposition, as a result
of humoral mediators of parasitic as well as host origin.
Inﬂammatory cells are gradually abolished, being replaced
by ﬁbroblasts. Granulomas shrink and may calcify. The pat-
tern of glomerular pathology is changed with more matrix
deposition and sclerosis.
Morbidity in schistosomiasis is notoriously much more
aggressive upon healing than with active pathology. Therefore,
the most serious manifestations of the disease occur many years
after infection. They include four categories, namely ﬁbrotic
lesions, glomerulonephritis, amyloidosis and malignancy.
Fibrotic lesions
Urinary
Healed schistosomal granulomas are associated with patchy or
conﬂuent ﬁbrosis and calciﬁcation. This often interrupts the
muscular layer of the bladder and ureteric walls, leading to
motor abnormalities of bladder function or disruption of the
internal vesical or ureterovesical sphincter mechanisms. Dif-
fuse ﬁbrosis may lead to cicatricial contraction in critical sites
including the ureter, ureterovesical junction or urethra leading
to respective obstructive manifestations, upstream backpres-
sure and ascending infection (Fig. 6, [27]). (See Barsoum’s arti-
cle on Urinary Schistosomiasis, in this issue of the Journal).
Hepato-intestinal
Chronic colonic manifestations are categorized into ‘‘chronic
sub mucosal colitis’’, and ‘‘chronic active sub mucosal colitis’’.
The former is characterized by sub mucosal scarring amidst
calciﬁed ova, and may lead to strictures in the left colon or rec-
tum. Active sub mucosal colitis also exhibits signs of active
granulomatous inﬂammation around live ova, with the forma-
tion of polyps or nodules. Neoplastic changes were reported in
up to one third, with frank malignant changes in 17.4% of
Chinese patients referred for colonoscopy [15], but this obvi-
ously constitutes a positive selection bias.
Chronic schistosomal colitis is often silent. Some patients
may complain of recurrent vague abdominal symptoms, in-fra-umbilical pain, ﬂatulence or disturbances of bowel habits.
Chronic diarrhea or rectal bleeding may mimic ulcerative coli-
tis. An occasional patient may develop a left pericolic mass
that may be clinically confused with diverticular disease or
malignancy, but the differential diagnosis can be readily re-
solved by colonoscopy or radio-imaging.
Chronic hepatic schistosomiasis is far more serious. It af-
fects immunogenetically predisposed young and middle-aged
adults [28]. Its severity correlates with the intensity of infection
[29]. Histologically, the hepatocytes are spared and the lobular
architecture is preserved. The ﬁbrotic, thickened portal tracts
appear as ‘‘pipe stems’’ which confer a characteristic histopa-
thological as well as ultrasonographic appearance (Fig. 7).
Eventually the liver shrinks, with typical pre-sinusoidal portal
hypertension, which manifests by splenomegaly, portosystemic
collaterals, and ascites. (See Elbaz and Esmat’s article on Hepa-
tic and Intestinal Schistosomiasis, in this issue of the Journal).
Cardio-pulmonary
S. haematobium ova may be carried to the right cardiac cham-
bers from the perivesical venous plexus via the inferior vena
cava, while S. mansoni or S. japonicum ova gain access across
portosystemic shunts. They usually stop short of the peri-alve-
Fig. 7 Schistosomal ‘‘pipestem ﬁbrosis’’. Ultrasonographic images in hepatic schistosomiasis. Note the central periportal ﬁbrosis (white
arrow) and ﬁbrosis on the periphery of the liver (red arrows) in a patient with advanced hepatosplenic schistosomiasis [30] (With
permission).
Fig. 8 ‘‘Bilharzial’’ cor pulmonale. (a) Chest X-ray showing
signs of pulmonary hypertension (prominent fourth arc – arrow).
(b) Ecocardiography in a patient with cor pulmonale in schisto-
somiasis mansoni: PA = trunk of the pulmonary artery;
AO = aorta. In normal people the diameter of the aorta is greater
than the trunk of the pulmonary artery. The relation here is
inverted (note the diameter between the blue crosses) [30] (With
permission).
Human Schistosomiasis: Clinical Perspective 439olar shunts where they lead to granuloma formation and also
provoke immune-mediated endothelial proliferation in both
pre-and post-alveolar capillaries (Fig. 8, [30,31]).
Obstructive pulmonary hypertension is the morbid physio-
logical expression of these lesions. This is usually asymptomatic,
or may be associated with shortness of breath. Cyanosis is unu-
sual since the obstruction is proximal to the level of pre-alveolar
shunts; butmay occur if peri-bronchial arteriovenous shunts are
opened. Clinical examination shows the typical signs of pulmon-
ary dilatation and hypertension. Right ventricular failure, with
severe tricuspid incompetence are terminal events.
Owing to the gradually progressive nature of the disease,
pulmonary artery dilatation may reach massive dimensions
as seen in radiological examination, associated with pulmon-
ary oligemia and right ventricular dilatation and hypertrophy.
Although, at autopsy, S. haematobium eggs are found in the
lungs twice as frequently as S. mansoni ova, the incidence of
cor pulmonale in patients with urinary schistosomiasis is much
lower compared to the 7.7–18.5% reported in those with hep-
atosplenic schistosomiasis [32]. It is unclear if S. haematobium
pulmonary disease is too mild to draw the patient’s or physi-
cian’s attention, or is simply under-reported, considering the
selective predominance of haematobiasis in sub-Saharan Afri-
ca, where reporting is exceptional. It is noteworthy, though,
that the antigenicity of S. haematobium is deﬁnitely less intense
than that of other schistosomal species, which may have a
bearing on this observation, as well as on incidence of glomer-
ulonephritis (See Barsoum’s article on Urinary Schistosomiasis,
in this issue of the Journal).
A restrictive pattern of right ventricular dysfunction was
observed in some of these patients. Endo-myocardial biopsy
showed considerable subendocardial ﬁbrosis, which is thought
to represent a diffuse form of the cellular response to schisto-
somiasis. The speciﬁcity of this lesion has yet to be conﬁrmed.
Chronic glomerulonephritis
Further to the early glomerular pathology described under sub
acute manifestations, glomerular lesions may progress into
mesangiocapillary, focal segmental sclerosis and global sclero-
sis in 15% of patients with hepato-intestinal schistosomiasis
[33]. This issue is addressed in detail in the article on Urinary
schistosomiasis in this issue of the Journal.
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Secondary amyloidosis can be induced by experimental infec-
tion with S. mansoni and S. japonicum in mice [34] and rabbits
[35], and with S. haematobium in hamsters [36]. It has also been
reported in patients with long-standing infection with S. man-
soni, S. haematobium, or both [37]. Co-infection with HCV
seems to favor amyloidogenesis due to complex immunological
interactions [26]. The lesions were usually restricted to the kid-
neys, and were associated with the conventional schistosoma-
associated glomerular and interstitial lesions. It is believed that
schistosoma-associated amyloidosis results from an imbalance
in-between the formation and uptake of AA protein by the
monocytes and hepatocytes. While synthesis is up-regulated
by IL-6, re-uptake is down-regulated by IL-10. The abundance
of these particular cytokines in established infection [38] may
add up to critically increase the level of circulating Serum A
protein in schistosomiasis [39]. Selective deposition in the
glomeruli is presumably related to the abundance of amyloid-
ophilic proteoglycans as decorin and biglycan [40].
Malignancy
Schistosomiasis has been associated with the development of
malignancy in the bladder [41], rectum [42] and lymphoid tis-
sue [43]; the pathogenic link being most ﬁrmly established with
the former. In addition, the association of hepatosplenic man-
soniasis with hepatitis B or C viral infections increases the risk
of liver malignancy and non-Hodgkin lymphomas many folds.
It is presumable that the predominant TH2 dominated sce-
nario in late schistosomiasis is largely responsible for increas-
ing the susceptibility to oncogenic provocations.
Bladder
Chronic urinary schistosomiasis is epidemiologically associ-
ated with squamous cell bladder cancer in Egypt and other
African foci. Nitrosamines, b-glucuronidase, and inﬂamma-
tory gene damage have been identiﬁed as possible carcinogenic
factors. Another explanation is that schistosomiasis lesions
intensify the exposure of the bladder epithelium to mutagenetic
substrates from tobacco or chemicals. (See Khaled’s article on
Schistosomiasis and Cancer, in this issue of the Journal).
Colorectal
Schistosomiasis is generally accepted as a risk factor for colo-
rectal cancer in Asia, where the infective species is S. japoni-
cum. Supportive reports are published from China [44],
Japan [45] and others, though there are still some question
marks about a true cause and effect relationship [46].
Lymphoma
A Burkitt’s type of lymphocytic lymphoma associated with S.
mansoni intestinal schistosomiasis was reported in a 14 year
old Zairian girl, with suggestive evidence of a cause and effect
relationship [43].
Co-infection
Attention has been drawn since the sixties of last century that
schistosmiasis is often associated with other parasitic, bacterialor viral infections [47], many of which may be endemic in the
same regions.
Parasitic infections
Co-infection with malaria and leishmaniasis has been well doc-
umented in experimental models as well as humans. In both
cases, schistosomiasis modiﬁed the course of the associated
infection, with little impact of the latter on schistosomal mor-
bidity. It seems that the concomitant immunity established in
between Schistosomes and their host interferes with the im-
mune response to the superadded infection.
West African patients with chronic mansoniasis who ac-
quire malaria are subject to severe disease with heavy parasite-
mia [48]. This does not occur in those with S. haematobium
infection, who even seem to be protected [49]. The mechanism
involved in this discrepancy remains unclear.
Reports from East Africa and South East Asia suggest that
recovery from Kala Azar is delayed in patients with hepatosp-
lenic schistosomiasis [50].
Co-infection of schistosoma and toxoplasma infection in
mice has been associated with augmented hepatotoxicity yet
without increase in tachyzoite counts. It was hypothesized that
excessive release of TNF-a was responsible for this injury, indi-
cating reactivation of earlier phases of immune response [51].
Schistosoma-ﬁlaria co-infection was reported from Egypt
[52]. It was shown that the clinical course of either parasite
is aggravated by prior infection with the other. Since the im-
mune response to these worms is similar, it is understandable
that concomitant immunity to either may induce relative toler-
ance to the other.
Bacterial infection
Schistosomiasis has been associated with several bacterial co-
infections including Salmonella, tuberculosis, staphylococcus
[47] and sexually transmitted diseases including Neisseria gon-
orrhea, Chlamydia trachomatis, Mycoplasma genitalium, and
Trichomonas vaginalis [53].
The most established of these, with highest impact on mor-
bidity is salmonellosis. This has been described with urinary
schistosomiasis since the late ﬁfties [54], as well as with hepato-
intestinal schistosomiasis a decade later [55]. Acute appendicitis,
cholecystitis, pyelonephritis and exudative glomerulonephritis
have been documented with this association.
Viral infection
Several viral infections are notoriously associated with schisto-
somiasis owing to the favorable immunological environment
caused by TH2 predominance [56]. These include Hepatitis B
and C, HIV and human papilloma virus [57].
Hepatitis viruses
A few decades ago, Hepatitis B (HBV) infection was a main
co-infective agent in hepato-intestinal schistosomiasis, infec-
tion being acquired during the intravenous administration of
tartar emetic for the treatment of schistosomiasis. It used to
confound the hepatic pathology by inducing hepatocellular
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soon became recognized as a signiﬁcant risk factor for the
development of hepatoma in those patients.
With the rapid decline of HBV incidence during the past 2
decades, Hepatitis C virus (HCV) replaced HBV as a frequent
co-infection in hepato-intestinal schistosomiasis. Infection
might have also been acquired along with intravenous anti-
schistosomal treatment, though other routes of infection re-
main unclear. HCV confounds hepatic pathology in a similar
pattern as HBV, including a dramatic increase in the risk of he-
patic malignancy (See Elbaz and Esmat’s article on Hepatic and
intestinal schistosomiasis, in this issue of the Journal). In addi-
tion, HCV confounds the glomerular lesions in hepatosplenic
schistosomiasis by adding the elements of cryoglobulinemia
and amyloidosis [26]. (See Barsoum’s article on Urinary
Schistosomiasis, in this issue of the Journal).
Human immunodeﬁciency virus
HIV is the most recent addition to the list of viral co-infection
with schistosomiasis. Studies showed that up to 17% of HIV-
infected patients from sub-Saharan Africa were seropositive
for schistosomiasis [58]. It was shown that women and men
with lower urinary schistosomiasis were at a signiﬁcantly in-
creased risk of acquiring, and subsequently transmitting HIV
to their sexual partners. There are three main clinical patterns
of schistosomiasis in such cases, namely gastrointestinal, dis-
seminated and neurological. Gastrointestinal schistosomiasis
is the most common and typically presents with weight loss,
diarrhoea, abdominal pain and odynophagia [59].
Neuroschistosomiasis (NSS) should be included in the dif-
ferential diagnosis in HIV-infected patients from endemic
areas who display an acute encephalopathy. While CT scan
and MRI are useful tools in the investigation of NSS, the
deﬁnitive diagnosis is based on the direct identiﬁcation of the
eggs in tissue biopsy [60]. There are promising, yet currently
less reliable serological methods including the detection of cir-
culating adult worm and soluble egg antigens by using mono-
clonal or polyclonal antibodies [61].
Management
Prevention
A schistosomiasis control program typically includes two ap-
proaches: (a) Control of morbidity, aiming at reducing the
number of severe form of the disease; and (b) Control of trans-
mission, by interrupting the evolutive cycle of the parasite
[62,63]. This includes sanitation and proper sewage control,
as well as limiting access to infested fresh water and provision
of safe water supply. Programs focused on eradication of snail
species have been attempted. In general, this approach does
not result in complete eradication and is difﬁcult to sustain;
repopulation by snails can occur very rapidly. Educational
programs also have a role.
Periodic mass treatment, which has become possible since
the introduction of the effective and safe oral drug, Praziquan-
tel [64], has also been very effective in China and Egypt. Ado-
lescents have been primarily targeted in these programs, being
the age group with the highest intensity of infection However,
there are certain drawbacks of mass treatment strategiesincluding logistic and ﬁnancial issues, possible development
of drug resistance, lack of resistance to re-infection and possi-
ble increase in the risk of hepatic disease with interrupted treat-
ment. For these reasons, the search for an effective vaccine
continues despite repeated disappointments with many at-
tempts in the past.
Vaccines
Data from animal vaccination studies has yielded important
information that shaped human vaccine-development strate-
gies. It is clear that an immune status is achieved by the inte-
gration of humoral and cellular mechanisms, dominated by
up-regulation of antigen-speciﬁc TH1and TH2 clones leading
to a favorable IgE/IgG4 ratio [65].
It remains to identify the right target antigen. More than 10
antigens with strong potential as vaccines candidates were
tried; most have been difﬁcult to move forward [65]. The most
eligible candidates are the schistosomular tegument membrane
antigens Sm 23, SmTSP-2 and Sm29. Also eligible are egg anti-
gens, targeting which would decrease parasite fecundity and
egg viability. A potential strategic approach would involve
multiple antigens together [66]. Proteomic and genomic studies
[65] are underway for integrating these antigens into a master
mix, hoping to raise the effectiveness of vaccination over the
current 70% success rate.
Treatment of active lesions
Active lesions readily respond to antischistosomal chemother-
apy. The drug of choice today is Praziquantel (PZQ), a pyraz-
inoisoquinoline derivative [67]. It is effective against all species
of human pathogenic schistosomes with a cure rate of 80%.
However, it cannot be used for chemoprophylaxis, since it is
active only against mature worms. The recommended thera-
peutic dose is 40 mg/kg body weight as a single morning dose
for S. haematobium and S. mansoni. For S. japonicum, the dose
should be increased to 60 mg/kg body weight given in two
divided doses on the same day. The same dose is used for
S. mekongi, preferably divided into three doses given in the
same day. The drug is safe, but a few side-effects have been re-
ported including abdominal pains, headaches, dizziness, and
skin rash. Resistance to PZQ in humans is still a rare occasion
in S. mansoni and not reported in S. haematobium.
The organophosphorus preparation metrifonate is effective
only against S. haematobium infections. The drug is safe and
can be used in mass treatment. The recommended dose is
10 mg/kg body weight as a single dose, which may be repeated
twice at fortnightly intervals in order to achieve a high cure
rate.
Oxamniquine is a quinoline derivative (2-aminomethyl-tet-
rahydro-quinoline), which is effective against S. mansoni only
infections. The recommended single-dose treatment is 20 mg/
kg body weight.
Artemether, a derivative of the Chinese antimalarial
Quyinghaosu alkaloids is a promising new agent that can effec-
tively kill the invading cercariae, maturing schistosomulae as
well as the mature adult worms by interfering with the
parasite’s glycolytic pathways [68]. It has been tried in
S. japonicum – endemic areas in southern China to prevent
new infections [69]; it was found to be active against other
442 R.S. Barsoum et al.human schistosomes and appears to be synergistic to PZQ in
killing adult worms.
Mirazid is an herbal drug derived from myrrh (puriﬁed
Commiphora molmol Engier) that was developed in Egypt.
The drug was found to be safe with no serious side effects.
However, its efﬁcacy has been debated; some studies showed
high efﬁcacy in the treatment of schistosomiasis and fasciolia-
sis [70] with a cure rate of 91.7%, whereas other authors have
found it to have a much lower cure rate than PZQ in their
studies [71]. Therefore, Botros and colleagues did not recom-
mend mirazid as an agent to control schistosomiasis [72].
Adjuvant treatment with colchicine has been successful in
reducing ﬁbrosis in experimental murine schistosomiasis [73]
and the development of amyloidosis in Syrian Hamsters [74].
It has been widely used in patients with hepatosplenic schisto-
somiasis, yet without conclusive therapeutic beneﬁt.
Results of treatment
Anti-schistosomal chemotherapy leads to parasitological cure
in 40–80% of cases, depending on the drug used, the parasite
species and strains, the host’s nutritional state, and other fac-
tors. Even without such a cure, the intensity of infection is sig-
niﬁcantly reduced [63]. The effectiveness of treatment can be
tested by the progressive decline in the number of eggs excreted
in urine and stools; to disappear within 3–4 months. Tissue
biopsy from the bladder or rectal mucosa after effective treat-
ment may still show trapped dead ova for many years. The ti-
ters of circulating gut and egg antigens rapidly decline with
effective treatment. Persistence of the former after the disap-
pearance of eggs from the excreta usually indicates the survival
of sterile or single-sex worms. This outcome has the advantage
of possibly conferring active immunity against re-infection, so
much so that it is considered the aim of certain mass treatment
programmes. Owing to the absence of ova, such a setting is
certainly harmless from the point of view of granulomatous le-
sions. However, its effect on the development and propagation
of immune-complex-mediated glomerular injury has not yet
been elucidated.
The reversibility of established lesions after effective antis-
chistosomal therapy depends on the species, the organ(s) af-
fected, the duration of infection, and the degree of damage
already sustained. Best results are achieved with early bladder
lesions or back pressure in S. haematobium infections, early co-
lonic or hepatic lesions in S. mansoni infections, or brain le-
sions in S. japonicum disease. Certain glomerular lesions
confounded by concomitant infections may be reversible by
dual therapy.
Treatment of ﬁbrotic lesions
Many of the residual lesions need no surgical correction.
Examples are colonic sub mucosal and pericolic ﬁbrosis spar-
ing motility, hepatosplenic schistosomiasis without portal
hypertension, lower ureteric ﬁbrosis without pelvicalyceal dila-
tation even when associated with mild to moderate reﬂux, and
bladder ﬁbrosis and calciﬁcation without signiﬁcant urody-
namic disturbances.
In certain instances, however, extreme degrees of portal
hypertension may necessitate shunting operations and
prominent oesophageal varices may require sclerotherapy.Lower urinary tract lesions are frequently treated by urological
procedures that include percutaneous nephrostomies for the
temporary relief of obstruction, endoscopic dilatation of ste-
nosed ureters, subureteric silicone injection for the ameliora-
tion of reﬂux, ureterovesical implantation, ureteroplasty and
cystoplasty, and the use of ileal loops for restoration of ade-
quate urodynamic function.
Owing to the silence of cardiopulmomary lesions, the diag-
nosis is usually delayed beyond the point of any reversibility.
Patients with schistosomal cor pulmonale tend to have pro-
gressive right ventricular failure, which is hardly affected by
any treatment.References
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